Annovis Bio
Develops oral buntanetap for Alzheimer's and Parkinson's disease.
Something off on this page? Send us feedback.
Profile
Advances buntanetap, an investigational oral therapy for Alzheimer's and Parkinson's disease. The founder-led company has no commercialized products and has historically funded operations through common-stock and warrant issuances.
Develops buntanetap, an investigational oral therapy for neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. The central program was licensed from the U.S. National Institute on Aging, and the company has no history of commercializing a pharmaceutical product.
Operations principally focus on preclinical and clinical studies. The pivotal early-Alzheimer's study is fully enrolled at U.S. sites. Founder, President and CEO Maria L. Maccecchini leads the clinical-stage organization. Commercialization of buntanetap depends on completing pivotal trials, receiving marketing approval, manufacturing at commercial scale, building sales and marketing capabilities, and securing additional capital.
Company facts
Key statistics
Year to date −52.9% · Average volume (30d) 560.4K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Jul 7, 2026 | Roth Capital | Initiate | Buy | |
| Feb 10, 2025 | D. Boral Capital | Downgrade | Buy | Hold |
| Oct 25, 2024 | Maxim Group | Upgrade | Hold | Buy |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q2 FY26 | −$0.45 | −$0.40 | +11.8% | — | — | — | +3.35% |
| May 15, 2026Q1 FY26 | −$0.40 | −$0.63 | −59.5% | — | — | — | −0.49% |
| Mar 16, 2026Q4 FY25 | −$0.31 | −$0.39 | −26.5% | — | — | — | −3.18% |
| Nov 12, 2025Q3 FY25 | −$0.36 | −$0.37 | −2.8% | — | — | — | −5.76% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$6.3M | −$6.3M | −$7.4M | −$9.7M | −$18.0M | −$14.4M | |
| Net income | −$5.5M | −$6.2M | −$7.3M | −$9.8M | −$17.6M | −$14.8M | |
| Diluted EPS | −$0.45 | −$0.32 | −$0.37 | −$0.40 | −$0.63 | −$0.39 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $18.7M · Total debt $0 · Total assets $22.0M · Shareholders' equity −$4.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 42.54M · Float 37.81M · 88.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Michael B. Hoffman · director | 3.29M | 7.74% | Form 4 | May 21, 2026 |
| Highbridge Capital Management, LLC | 2.78M | 6.10% | 13G | Aug 14, 2026 |
| Empery Asset Management, LP | 2.40M | 5.64% | 13G | Jul 29, 2026 |
| Marshall Wace, LLP | 1.84M | 4.33% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 1.65M | 3.87% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 20, 2026 | Michael B. Hoffman | director | +76,344 | $1.87 |
| Apr 2, 2026 | Michael B. Hoffman | director | +713,800 | $2.10 |
| Dec 8, 2025 | Michael B. Hoffman | director | +45,000 | $4.31 |
| Nov 24, 2025 | Michael B. Hoffman | director | +39,200 | $4.08 |
| Nov 21, 2025 | Michael B. Hoffman | director | +20,000 | $3.50 |
Peers
- Eli Lilly
Approved early-AD amyloid therapy with monthly IV dosing
- Biogen
Co-commercialized early-AD anti-amyloid treatment
- AbbVie
Late-stage once-daily therapy program for early Parkinson's disease
- Bristol-Myers Squibb
Phase 2 anti-MTBR-tau antibody program for early Alzheimer's disease
- Cognition Therapeutics
Once-daily oral candidate in an ongoing early-AD Phase 2 trial
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Annovis Bio | $1.74 | +1.16% | $73.2M | — | — | — | — |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Biogen | $218.19 | −0.14% | $32.28B | 38.7 | 16.5 | 3.2 | +3.4% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Cognition Therapeutics | $1.04 | +1.99% | $91.3M | — | — | — | — |
| Median | 39.0 | 16.7 | 5.1 | +8.0% |